Inmune Bio, Inc. (36)
Browse by Contract Category
Contracts
-
Amendment No. 2 to Rights Agreement, dated as of December 9, 2022, between the Company and VStock Transfer LLC, as Rights Agent
(Filed With SEC on December 12, 2022)
-
Form of Securities Purchase Agreement
(Filed With SEC on March 24, 2022)
-
Lease Agreement dated September 13, 2021
(Filed With SEC on September 15, 2021)
-
Form of Placement Agency Agreement
(Filed With SEC on July 15, 2021)
-
First Amendment to License Agreement
(Filed With SEC on June 15, 2021)
-
INmune Bio, Inc. 2021 Stock Incentive Plan
(Filed With SEC on June 3, 2021)
-
Form of Option Agreement for Employees of the Company
(Filed With SEC on March 24, 2022)
-
Form of Option Agreement between the Company and Non-Employee Directors and consultants
(Filed With SEC on March 24, 2022)
-
Description of Securities of INmune Bio, Inc
(Filed With SEC on March 3, 2022)
-
Amendment No. 1 to Rights Agreement, dated as of December 20, 2021, between INmune Bio Inc. and Vstock Transfer, LLC
(Filed With SEC on December 21, 2021)
-
Form of Securities Purchase Agreement
(Filed With SEC on July 15, 2021)
-
Form of Option Agreement for Employees of the Company
(Filed With SEC on June 24, 2021)
-
Form of Option Agreement between the Company and Non-Employee Directors
(Filed With SEC on June 24, 2021)
-
Warrant to Purchase Common Stock issued to Silicon Valley Bank
(Filed With SEC on June 15, 2021)
-
Warrant to Purchase Common Stock issued to SVB Innovation Credit Fund VIII, L.P
(Filed With SEC on June 15, 2021)
-
Loan and Security Agreement
(Filed With SEC on June 15, 2021)
-
Option Cancellation Agreement between INmune Bio Inc. and Xencor, Inc
(Filed With SEC on June 15, 2021)
-
Form of agreement between INmune Bio Inc. and National Securities Corporation, dated March 29, 2021
(Filed With SEC on March 29, 2021)
-
At-The-Market Sales Agreement, dated March 10, 2021, between the Company and BTIG
(Filed With SEC on March 11, 2021)
-
Employment Agreement effective as of January 1, 2021 between INmune Bio Inc. and David Moss (attached hereto)
(Filed With SEC on March 4, 2021)
-
Employment Agreement effective as of January 1, 2021 between INmune Bio Inc. and Raymond J. Tesi (attached hereto)
(Filed With SEC on March 4, 2021)
-
Rights Agreement, dated as of December 30, 2020, by and between INmune Bio Inc. and VStock Transfer, LLC
(Filed With SEC on January 4, 2021)
-
Rights Agreement, dated as of December 30, 2020, by and between INmune Bio Inc. and VStock Transfer, LLC
(Filed With SEC on December 30, 2020)
-
Amendment to Exclusive License Agreement
(Filed With SEC on November 5, 2020)
-
Amendment No. 1 to At-The-Market Sales Agreement, dated April 16, 2020, between the Company and BTIG
(Filed With SEC on August 19, 2020)
-
Underwriting Agreement, dated July 16, 2020, by and between INmune Bio, Inc. and BTIG, Inc., as representative of the underwriters named therein
(Filed With SEC on July 16, 2020)
-
At-The-Market Sales Agreement, dated April 16, 2020, between the Company and BTIG
(Filed With SEC on April 17, 2020)
-
INmune Bio, Inc. 2019 Stock Incentive Plan (attached hereto)
(Filed With SEC on March 11, 2020)
-
Award Agreement dated as of February 4, 2020
(Filed With SEC on February 10, 2020)
-
Common Stock Repurchase Agreement
(Filed With SEC on January 27, 2020)
-
Amendment No. 2 to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi
(Filed With SEC on May 24, 2019)
-
Amendment to Securities Purchase Agreement between INmune Bio, Inc. and David J. Moss
(Filed With SEC on May 17, 2019)
-
Amendment to Securities Purchase Agreement between INmune Bio, Inc. and Raymond J. Tesi
(Filed With SEC on May 17, 2019)
-
Registration Rights Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC, dated May 15, 2019
(Filed With SEC on May 16, 2019)
-
Purchase Agreement between INmune Bio Inc. and Lincoln Park Capital Fund, LLC, dated May 15, 2019
(Filed With SEC on May 16, 2019)
-
Award Letter dated as of February 22, 2019 from the Alzheimers Association to INmune Bio, Inc
(Filed With SEC on February 28, 2019)